CING

Cingulate Inc.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc. (CING) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (C). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
B-
Factor Score 2.9 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.2
EV / EBITDA -1.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -12.5%
Price Return 12M 22.3%
Catalyst Signal 0.00
Market Cap $66.3M
TTM Revenue N/A
Price / Sales N/A
ROE -198.7%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) B- (2.9) C (2.5) B- (2.9) C+ (2.6) C+ (2.7)
2026-11-04 C+ (2.5) B- (2.9) C+ (2.6) B- (2.9) C+ (2.7) C+ (2.7)
2026-10-28 C+ (2.5) C+ (2.8) C+ (2.6) B (3.2) C+ (2.7) C+ (2.8)
2026-10-21 C+ (2.5) C+ (2.8) C+ (2.5) C+ (2.6) C+ (2.6) C+ (2.6)
2026-10-14 C+ (2.5) C+ (2.8) C+ (2.5) B- (2.9) C+ (2.6) C+ (2.7)
Page 1 of 4